The Diagnostic and Clinical Significance of TFE3 Immunohistochemical Nuclear Expression in Solitary Fibrous Tumour

Abstract EN

The expression of TFE3 (transcription factor E3) in solitary fibrous tumours (SFTs) and their histologic mimickers was investigated, and the diagnostic value and clinical significance of TFE3 nuclear expression in SFTs were explored.

Immunohistochemical analysis for TFE3 was performed on 50 cases of SFTs that were surgically resected.

The controls were sample tissues from malignant peripheral nerve sheath tumour, synovial sarcoma, dedifferentiated liposarcoma, spindle cell lipoma, and dermatofibrosarcoma protuberans.

The survival of patients with TFE3-positive and TFE3-negative expressions was assessed through the Kaplan-Meier analysis.

In 44 of 50 (88%) SFTs, nuclear immunoreactivity for TFE3 was detected.

The TFE3 expression was negative in all samples of synovial sarcoma, malignant peripheral nerve sheath tumour, dermatofibrosarcoma protuberans, and spindle cell lipoma and weakly positive in 2 of 10 cases of dedifferentiated liposarcoma.

Fluorescence in situ hybridization (FISH) confirmed that the expression of the TFE3 protein is not caused by gene translocation.

There was no statistical significance between the association of the TFE3 expression and SFT patient prognosis.

Therefore, TFE3 is capable of enhancing the differential diagnosis of SFTs and their histologic mimickers and can be potentially used as a diagnostic marker.

The findings also offer valuable insights into SFT diagnosis, aetiology, and associated molecular mechanisms.